Fundraising Fox
bioTheranostics
San Diego, US · Founded 2008 · Delaware corporation · 97 employees on LinkedIn · 3 known investors
Find your way into bioTheranostics
Sign up to see every warm intro you have to bioTheranostics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the bioTheranostics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology. The company was acquired by Hologic in February 2021.
Founders & leadership
NB
Nicholas BarthelemyExecutive
Board
DK
EB
AS
Investors · 3
Evidity Health Capitallisted by Evidity Health CapitalNew York · $5M
How we know: Evidity Health Capital's portfolio page · Not right? Tell us
HealthQuest CapitalreportedRedwood City
How we know: funding news · Not right? Tell us
MVM Life Science PartnersreportedLondon · $20M – $100M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$20M disclosed across 1 round · 2016
▶$20MraisedFeb 2016 · 4 investors · Other Health CareRule 506(b)
▶$20MraisedFeb 2016 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas BarthelemyExecutive Officer, Director, Promoter
- David KabakoffDirector
- Eric BednarskiDirector
- Alejandro SanchezDirector
- Offering amount
- $32M
- Amount sold
- $20M
- Sales commissions
- $1.6M
- Placement agents
- Piper Jaffray & Co.
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does bioTheranostics do?
- Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology. The company was acquired by Hologic in February 2021.
- Who are bioTheranostics's investors?
- bioTheranostics's investors include Evidity Health Capital, HealthQuest Capital, MVM Life Science Partners.
- How much funding has bioTheranostics raised?
- bioTheranostics has disclosed $20M raised across 1 round.
- Where is bioTheranostics headquartered?
- bioTheranostics is headquartered in San Diego, US.